Bionexus选择以太坊而不是比特币进行国库策略

2025年3月5日，位于马来西亚的Bionexus Gene Lab，通过宣布将以太坊（ETH）优先于比特币（BTC）的决定，成为了关键新闻。

BioNexus Gene Lab (Nasdaq:BNXS), a publicly listed company based in Malaysia and focused on gene technology, has made the strategic decision to prioritize allocating its treasury assets into Ethereum (ETH) over Bitcoin (BTC).

Bionexus Gene Lab（NASDAQ：BNXS）是一家位于马来西亚的公开上市公司，专注于基因技术，已做出战略决定，优先考虑将其财政资产分配给比特币（BTC）的以太坊（ETH）。

This decision, announced on March 5, 2025, positions BioNexus as potentially the first Nasdaq-listed institution to adjust its treasury strategy toward a primary holding of a blockchain asset.

该决定于2025年3月5日宣布，将Bionexus定位为第一个将其财政策略调整为主要持有区块链资产的纳斯达克上市机构。

The institution’s internal analysis, approved by its Board of Directors, identified several factors influencing their choice of Ethereum. Among these was the U.S. administration’s decision to include ETH in the government’s Crypto Strategic Reserve.

该机构的内部分析得到了董事会的批准，确定了影响以太坊选择的几个因素。其中包括美国政府决定将ETH纳入政府的加密战略储备中。

Another key factor was the potential for staking on Ethereum, which allows companies to generate additional yields of 3% to 5% annually, in contrast to Bitcoin which is traditionally used as a store of value.

另一个关键因素是在以太坊上占用的潜力，这使公司每年产生3％至5％的额外收益率，而比特币通常用作价值存储。

“Ethereum offers high liquidity, utility, and stability compared to other digital assets, positioning BGLC as a leader in blockchain-integrated corporate finance,” said Sam Tan, CEO of BioNexus.

Bionexus首席执行官Sam Tan说：“与其他数字资产相比，以太坊提供了高流动性，公用事业和稳定性，将BGLC定位为区块链集成公司融资的领导者。”

The company, which had a market cap of $6 million, revenue of $2.6 million, and net income of negative $1.3 million as of September 30, 2024, is optimistic about this strategic pivot.

截至2024年9月30日，该公司的市值为600万美元，收入为260万美元，净收入为130万美元，对这一战略枢纽非常乐观。

This decision also follows the creation of a favorable regulatory environment for blockchain businesses in Wyoming, with the passing of the “Wyoming Stable Token Act” in March 2023 being particularly relevant.

这项决定还遵循了怀俄明州为区块链业务建立一个有利的监管环境，而2023年3月的“怀俄明州稳定代币法”的通过特别相关。

The Act allows the Wyoming Stable Token Commission to issue tokens that are exchangeable for U.S. dollars, aligning with BioNexus’s innovative, forward-thinking approach.

该法案允许怀俄明州稳定的代币委员会发布可以美元交换的代币，与Bionexus的创新，前瞻性的方法保持一致。

BioNexus elaborates further on Ethereum’s advantages over Bitcoin in its whitepaper titled “ETH Strategy.” The institution explains how Ethereum serves not only as digital currency but also the settlement layer for various stablecoins like Tether USD (USDT) and USD Coin (USDC).

Bionexus在其白皮书“ ETH策略”中进一步阐述了以太坊比比特币的优势。该机构解释了以太坊不仅如何用作数字货币，而且如何使用Tether USD（USDT）和USD Coin（USDC）等各种Stablecoin的结算层。

The system handles vast transaction volumes, reported as trillions of dollars annually, bolstering its role as central to the burgeoning digital economy.

该系统处理庞大的交易量，据报道每年数万亿美元，增强了其对新兴数字经济的核心作用。

Moreover, the whitepaper delves into how Ethereum’s capabilities, spanning tokenization of financial assets, decentralized payments, and enhanced regulatory compliance, render it especially appealing to banks, investment firms, and publicly traded companies. These institutions are increasingly adopting Ethereum as a component of their financial architectures.

此外，白皮书还深入研究以太坊的能力，跨越金融资产的令牌化，分散付款以及增强的监管合规性，使其对银行，投资公司和上市公司特别有吸引力。这些机构越来越多地采用以太坊作为其金融体系结构的组成部分。

Finally, BioNexus anticipates utilizing Ethereum exchange-traded funds (ETFs) more frequently, reflecting the growing institutional acceptance of ETH. The institution’s strategy also implies support for the upcoming Ethereum upgrades, with excitement building around the Pectra update scheduled for April 2025.

最后，Bionexus预计会更频繁地利用以太坊交换的资金（ETF），反映出ETH的制度知识不断增长。该机构的战略还意味着支持即将进行的以太坊升级，围绕Pectra更新的兴奋性建设计划于2025年4月。

This update promises to improve wallet functionalities, validator operations, network performance, smart contract deployment, and account abstraction, highlighting its commitment to leveraging Ethereum’s innovation.

此更新有望改善钱包功能，验证器操作，网络绩效，智能合同部署和帐户抽象，强调其对利用以太坊的创新的承诺。